{"id":"W3202506818","doi":"10.1016/j.annonc.2021.08.1092","title":"579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec","funders":"Pharmacyclics; Genentech; Astellas Pharma; Eisai; Endocyte; Advanced Accelerator Applications; Incyte; Clovis Oncology; Exelixis; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Internal medicine; Cohort; Prostate cancer; Oncology; Nivolumab; Anemia; Docetaxel; Cancer; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000975482,0.0008407507,0.001193209,0.0003719041,0.0006443553,0.001523607,0.0009393861,0.0006652974,0.01068342],"category_scores_gemma":[0.001645214,0.0005333071,0.004477189,0.0004083062,0.0002566736,0.0007739965,0.0006706563,0.001472995,0.002012696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009002168,"about_ca_system_score_gemma":0.001629041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01441733,"about_ca_topic_score_gemma":0.02674421,"domain_scores_codex":[0.9993698,0.0001410661,0.00002938744,0.0001938424,0.00007790993,0.0001879938],"domain_scores_gemma":[0.9993731,0.0001101796,0.0001174188,0.0001699208,0.00008181933,0.0001474977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2485097,0.001975342,0.5860112,0.0009577282,0.02689617,0.0009491199,0.0001962187,0.005310523,0.009076604,0.001193763,0.06688738,0.05203622],"study_design_scores_gemma":[0.02083002,0.01190407,0.8849893,0.0004296073,0.01664738,0.001021047,0.0004584671,0.007315368,0.003222352,0.002165738,0.05088925,0.0001274994],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9198875,0.003368096,0.001736687,0.0008912407,0.0004940187,0.0004222206,0.06487583,0.0002224444,0.008101906],"genre_scores_gemma":[0.9268172,0.0006145317,0.0008443575,0.0009511341,0.0002341443,0.0003721017,0.05765722,0.0001395897,0.01236976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01441733,"threshold_uncertainty_score":0.0357396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1338087969553961,"score_gpt":0.4506954352049392,"score_spread":0.316886638249543,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}